Results: 1053 consecutive non-HD patients who underwent AF ablation. Procedural complications were evaluated and compared to those of baseline and 6 months after the ablation. Ablation outcomes and QoL were assessed with the Kidney Disease Quality of Life Short Form (KDQOL-SF) to evaluate the QoL of the HD patients. Nineteen patients undergoing HD (14 men, age 68 ± 8 years; 15 with paroxysmal AF) who underwent catheter ablation (CA) of AF were enrolled in the study. The Kidney Disease Quality of Life Short Form (KDQOL-SF) was assessed to evaluate the QoL of the HD patients at baseline and 6 months after the ablation. Ablation outcomes and procedural complications were evaluated and compared to those of 1053 consecutive non-HD patients who underwent AF ablation.

Methods: Nineteen patients undergoing HD (14 men, age 68 ± 8 years; 15 with paroxysmal AF) who underwent catheter ablation (CA) of AF were enrolled in the study. The Kidney Disease Quality of Life Short Form (KDQOL-SF) was assessed to evaluate the QoL of the HD patients at baseline and 6 months after the ablation. Ablation outcomes and procedural complications were evaluated and compared to those of 1053 consecutive non-HD patients who underwent AF ablation.

Results: The KDQOL-SF of the HD patients 6 months after the ablation showed an improvement in physical functioning (54 ± 23 to 68 ± 28, P < 0.01), general health perceptions (38 ± 17 to 48 ± 15, P < 0.01), and quality of life (QoL) (39 ± 13 to 47 ± 14, P < 0.01). The KDQOL-SF of the HD patients 6 months after the ablation were significantly different from those of 1053 non-HD patients

Original Article

Improvement in Quality of Life via Catheter Ablation for Atrial Fibrillation in Patients Undergoing Hemodialysis Therapy

Masato Hachisuka, MD,a Hiroshi Hayashi, MD, PhD,a Yu-ki Iwasaki, MD, PhD,a Nobuaki Ito, MD,a Toshiki Arai, MD,a Serina Kobayashi, MD,a Rei Mimuro, MD,a Yuhi Fujimoto, MD, PhD,a Eiichiro Oka, MD, PhD,a Kanako Hagiwara, MD, PhD,a Ippei Tsuboi, MD, PhD,b Hiroshige Murata, MD, PhD,a Teppei Yamamoto, MD, PhD,a Michio Ogano, MD, PhD,b Kenji Yodogawa, MD, PhD,a Meiso Hayashi, MD, PhD,a,c and Wataru Shimizu, MD, PhDa

Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan

Department of Cardiovascular Medicine, National Hospital Organization Shizuoka Medical Centre, Shizuoka, Japan

Mabori Medical Clinic, Yokosuka, Japan

ABSTRACT

Background: Atrial fibrillation (AF) is the most common arrhythmia in patients undergoing hemodialysis (HD); AF lowers quality of life (QoL) and increases the risk of dialysis-related complications. The present study aimed to evaluate the effectiveness of AF ablation on the QoL in patients undergoing HD.

Methods: Nineteen patients undergoing HD (14 men, age 68 ± 8 years; 15 with paroxysmal AF) who underwent catheter ablation (CA) of AF were enrolled in the study. The Kidney Disease Quality of Life Short Form (KDQOL-SF) was assessed to evaluate the QoL of the HD patients at baseline and 6 months after the ablation. Ablation outcomes and procedural complications were evaluated and compared to those of 1053 consecutive non-HD patients who underwent CA.

Results: The KDQOL-SF of the HD patients 6 months after the ablation showed an improvement in physical functioning (54 ± 23 to 68 ± 28, P < 0.01), general health perceptions (38 ± 17 to 48 ± 15, P < 0.01), and quality of life (QoL) (39 ± 13 to 47 ± 14, P < 0.01). The KDQOL-SF of the HD patients 6 months after the ablation were significantly different from those of 1053 non-HD patients who underwent CA.

The increasing epidemic of chronic kidney disease and end-stage renal disease is a serious problem, and the number of patients who need to receive maintenance hemodialysis (HD) therapy is rising worldwide. Patients undergoing HD therapy have a lower quality of life (QoL) than the general healthy population, due to the intrusiveness of the required treatment. Improving the QoL in patients receiving HD therapy is an essential issue, as a low QoL is a risk factor for all-cause and cardiovascular mortality, and an improved QoL is associated with positive effects in terms of laboratory values, mortality, and adherence to the therapy.

Atrial fibrillation (AF) is frequently observed in patients undergoing HD, with a prevalence of 8%-28%. The present study aimed to evaluate the effectiveness of AF ablation on the QoL in patients undergoing HD. The increasing epidemic of chronic kidney disease and end-stage renal disease is a serious problem, and the number of patients who need to receive maintenance hemodialysis (HD) therapy is rising worldwide.

Received for publication May 10, 2022. Accepted May 31, 2022.

Ethics Statement: The study protocol conformed to the Declaration of Helsinki, and the present study was conducted with the prior approval of the Ethics Committee of Nippon Medical School Hospital. All the patients gave written informed consent for the catheter ablation.

Corresponding author: Dr Hiroshi Hayashi, Department of Cardiovascular Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. Tel.: 81-3-3822-2131 x24007; fax: 81-3-5685-0987. E-mail: s00-067@nms.ac.jp
See page 755 for disclosure information.
and symptoms/problems (75 ± 21 to 84 ± 13, P = 0.02), compared to baseline. For intradialytic symptoms, dyspnea during HD significantly improved after the CA in the HD patients without AF recurrence (43% to 7%, P = 0.04), whereas the atrial tachyarrhythmias and hypotension during HD remained unchanged. During the follow-up period of 17 ± 13 months after the last procedure, the incidence of being arrhythmia-free was similar (HD patients, 79% vs non-HD patients, 86%, log-rank P = 0.82). No life-threatening complications occurred in any of the patients.

Conclusions: CA of AF improves QoL in patients undergoing chronic HD therapy.

response during HD can result in intradialytic complications, including palpitations, dyspnea, and chest pain. Moreover, AF during HD causes hemodynamic compromise, leading to an interruption in the HD. The negative impact of AF on the QoL in patients undergoing HD therapy is assumed to be a more serious clinical problem than AF in patients who are not receiving maintenance HD therapy.

Recently, catheter ablation (CA) has become a first-line therapy for AF, and previous reports have examined CA of AF in patients undergoing HD therapy. Although those studies showed that CA may be a reasonable initial procedure in HD patients as a rhythm-control therapy, little is known about its effect on QoL, especially during HD. The purpose of the current study was to examine whether the elimination of AF by CA improves QoL in patients undergoing HD therapy.

Methods

Study population

From January 2017 to December 2020, a total of 19 consecutive patients on ongoing HD who underwent their first CA of AF at Nippon Medical School Hospital were retrospectively enrolled in the current study. All the HD patients underwent an assessment of their QoL, at baseline and after the ablation. The ablation outcomes were also examined and compared with those in the 1053 consecutive patients who were not receiving HD therapy, who underwent their initial CA of AF during the same period. The patients were excluded if they had a history of CA or surgery for AF, or were unable to receive follow-up evaluation at the study site. The CA of AF was performed based on current guidelines. The study protocol conformed to the Declaration of Helsinki, and the study was conducted with the prior approval of the Ethics Committee of Nippon Medical School Hospital. All the patients provided written informed consent for CA.

Electrophysiologic study and catheter ablation

All antiarrhythmic drugs were discontinued for at least 5 half-lives before the CA was performed. Amiodarone was discontinued more than 1 month before the CA. All the HD patients received appropriate oral anticoagulation therapy with warfarin (international normalized ratio 2.0-3.0) for at least 3 weeks, and warfarin was continued throughout the peri-procedural period. In the non-HD patients, administration of oral anticoagulants was skipped only on the day of the CA and was restarted on the morning of the first postoperative day. After written consent was obtained, CA was performed with patients under deep sedation using midazolam and dexmedetomidine. The intracardiac electrograms and surface electrocardiograms were continuously monitored and recorded using the EP Workmate (St. Jude Medical, Minneapolis, MN). A 20-polar catheter with 2–2.2 mm interelectrode spacing (BeeAT, Japan LifeLine Co., Ltd, Tokyo, Japan) was introduced from the right internal jugular vein and advanced into the coronary sinus. A transseptal puncture was performed using the RF needle (Baylis Medical, Montreal, Quebec, Canada) inserted through a long sheath (SL 0 and/or SL 8.5, St. Jude Medical). Heparin was initiated before the transseptal puncture, and an activated clotting time of 300-350 seconds was maintained with continuous administration of heparin during catheter manipulation and the ablation procedure in the left atrium (LA). After transseptal access, one or two 7-F duo-decapolar circular mapping catheters (Lasso, Biosense Webster, Diamond Bar, CA, or Optima, Abbott, Abbot Park, IL) and an irrigated ablation catheter (SmartTouch, Biosense Webster Inc. or FlexAbility, Abbott) were inserted into the LA. A steerable sheath (Agilis, St. Jude Medical) was used for the ablation catheter in all procedures. The procedures were guided with an electroanatomic mapping system: CARTO system (Biosense Webster Inc.) or Ensite Velocity system (Velocity, Abbott) in which the 3-dimensional reconstructed computerized tomography images of the LA and pulmonary veins (PVs) were merged with real-time anatomic maps. The radiofrequency power was delivered at 30-40W to the LA, and was reduced to 20W inside the coronary sinus. The upper limit of the esophageal temperature was set as 39.5°C to prevent esophageal thermal damage. The endpoint of the ablation was the complete isolation of all 4 pulmonary veins (PVs). Decisions about whether to create linear lesions—that is, a roof line, an inferior-posterior line, a mitral isthmus line, a cavotricuspid isthmus line, and isolation of the superior vena
cava—and whether to perform ablation of complex fractionated atrial electrograms (CFAEs) and non-PV triggers were left up to the discretion of each operator.

**Follow-up**

After discharge from the hospital, the patients were seen in the outpatient clinic every month for the first 3 months, and every 2 or 3 months thereafter. The antiarrhythmic drug therapy used during the follow-up period was determined by the individual physician. In the case of an AF recurrence, which was confirmed by electrocardiograms after the 3-month blanking period, we offered to perform a second CA procedure in which a re-isolation was made if reconnections of the PVs and linear lesions were documented. The oral anti-coagulants were discontinued when AF had not recurred after the 3-month blanking period in all the HD patients and in the non-HD patients with a Congestive Heart Failure, Hypertension, Age ≥75, Diabetes, and Prior Stroke/Transient Ischemic Attack (doubled) (CHADS2) score of <2.

**Assessment of QoL and intradialytic complications**

Among the HD patients, QoL was evaluated using the Japanese version of Kidney Disease Quality of Life Short Form version 1.3 (KDQOL-SF 1.3), which is designed for studies of patients undergoing HD therapy and has been used worldwide for the assessment of QoL in these patients. The Japanese version has been validated for use in Japanese populations, and internal consistency and reliability tests were carried out. The KDQOL-SF 1.3 consists of 36 comprehensive questions about general physical and mental state of health (short form 36 [SF-36] Japanese version 1.2), and 43 questions related specifically to renal failure. Those 43 questions focused on the following issues that patients receiving dialysis therapy experience: symptoms, effects of kidney disease on daily life, renal failure weight, dialysis staff encouragement, and patient satisfaction. The KDQOL-SF 1.3 was evaluated prior to and 6 months after the first ablation. If AF recurred or post-ablation atrial tachycardia occurred, the post-ablation KDQOL-SF 1.3 assessment was performed at least 3 months after the last ablation procedure.

In the present study, the incidence of intradialytic complications, defined as any symptoms that occurred during the HD session, was evaluated at baseline and after the CA. Interruption of HD caused by tachycardic AF or intradialytic complications, defined as any symptoms that occurred during the first 3 months, and whether to perform ablation of complex fractionated atrial electrograms (CFAEs) and non-PV triggers were left up to the discretion of each operator.

**Statistical analysis**

The data are expressed as mean ± standard deviation, or median (interquartile range), for continuous variables, and as absolute frequencies and percentages for categorical variables. The differences between the HD and non-HD patients were compared, using a Student t-test or Mann-Whitney U test, for continuous variables and for categorical variables, the Fisher exact test. The results of the answers to the KDQOL-SF 1.3 assessment were converted from the original scores into corresponding scores ranging from 0 to 100 using directions in the manual specialized for this purpose, and the mean values of the scores belonging to each subscale were calculated. The differences between the QoL score before and after the ablation were compared using a paired-samples t-test. All tests were 2-sided, and a P value of <0.05 was considered statistically significant. A Kaplan-Meier analysis and log-rank test were performed in order to present and compare the primary outcome of the HD and non-HD patients. All statistical analyses were conducted using SPSS 25.0 software (IBM Inc., Armonk, NY).

**Results**

**The comparison of the QoL score before and after the ablation**

Among the 19 HD patients, questionnaire results after the ablation were not available for 1 patient who died 19 months after the last ablation. The KDQOL-SF 1.3 evaluation was made in the remaining 18 patients, at baseline and 6 months after the ablation procedure (Table 1). Among the SF-36 components, physical functioning (P = 0.009) and general health perceptions (P = 0.001) significantly improved after the ablation. Regarding the kidney-disease-targeted scales, the measure of symptoms/problems showed statistical improvement after the ablation (P = 0.022). No difference occurred in the other scales, including the mental health, social interaction, and patient satisfaction measures.

**Complications during HD**

Among the 18 HD patients who completed the questionnaire, intradialytic complications were documented in 17 patients (94%). The most common complication that occurred during HD before the CA was palpitations (n = 12), a finding that did not change after the ablation (67% vs 56%, P = 0.494; Supplemental Table S1). However, among the patients who remained free from AF recurrence after the last

---

**Table 1. Changes in the Kidney Disease Quality of Life Short Form version 1.3 (KDQOL-SF 1.3) before and after catheter ablation (CA) in the hemodialysis patients**

| Scale (no. of items) | Before CA (n = 18) | After CA (n = 18) | P     |
|----------------------|-------------------|------------------|-------|
| SF-36                |                   |                  |       |
| Physical functioning (10) | 54.4 ± 22.9       | 68.4 ± 28.3      | **0.009** |
| Physical role functioning (4) | 48.6 ± 48.1       | 52.7 ± 43.6      | 0.053  |
| Bodily pain (2)       | 75.8 ± 29.0       | 81.2 ± 26.5      | 0.285  |
| General health perceptions (5) | 38.3 ± 16.9       | 48.0 ± 15.1      | **0.001** |
| Vitality (4)          | 52.7 ± 24.2       | 59.5 ± 22.5      | 0.236  |
| Social functioning (2) | 77.7 ± 25.2       | 80.5 ± 23.5      | 0.607  |
| Emotional role functioning (3) | 50.0 ± 46.0       | 70.3 ± 41.0      | 0.052  |
| Mental health (3)     | 60.8 ± 21.6       | 69.1 ± 21.0      | 0.112  |

Kidney-disease-targeted

| Symptoms/Problems (12) | 74.7 ± 20.8 | 83.5 ± 12.5 | **0.022** |
| Effect of kidney disease (8) | 55.7 ± 36.2 | 64.4 ± 31.3 | 0.148 |
| Burden of kidney disease (4) | 28.4 ± 19.9 | 28.8 ± 21.2 | 0.905 |
| Work status (2)         | 52.9 ± 41.3 | 58.8 ± 44.1 | 0.163 |
| Cognitive function (3)  | 78.5 ± 18.0 | 84.4 ± 18.1 | 0.111 |
| Quality of social interactions (3) | 81.8 ± 18.5 | 82.9 ± 21.1 | 0.823 |
| Sexual function (2)     | 13.8 ± 32.3 | 17.3 ± 31.8 | 0.399 |
| Sleep (4)               | 66.2 ± 13.1 | 64.8 ± 14.4 | 0.733 |
| Social support (2)      | 72.2 ± 32.3 | 75.9 ± 25.7 | 0.361 |
| Dialysis staff encouragement (2) | 72.2 ± 30.4 | 73.6 ± 30.5 | 0.798 |
| Patient satisfaction (1) | 69.4 ± 37.1 | 69.4 ± 34.8 | 1.0   |

Values are mean ± standard deviation, unless otherwise indicated. Boldface indicates significance.

SF-36, short form 36.
CA (n = 14), the dyspnea during HD significantly improved after the ablation (43% vs 7%; P = 0.038; Table 2). Among the 17 patients, an interruption of HD was observed in 4 patients, and the reasons for interruption were hypotension (n = 2), palpitation (n = 1), and chest pain (n = 1). Although those 4 patients remained free from an arrhythmia recurrence after the last ablation, interruption of HD still occurred.

CA outcomes

The ablation outcomes of the HD patients were compared with those of the non-HD patients who underwent initial CA for AF at the same time. The baseline characteristics of the study population are summarized in Table 3. The HD patients had a significantly lower body mass index (P = 0.048), a higher Congestive Heart Failure, Hypertension, Age (≥ 75 Years) (doubled), Diabetes Mellitus, Stroke (doubled), Vascular Disease, Age (65-74 Years, Sex Category (Female) (CHA\(_2\)DS\(_2\)-VASc) score (P = 0.001), and a higher prevalence of vascular disease (P < 0.001), hypertension (P < 0.001), and diabetes mellitus (P < 0.001) than the non-HD patients. The hemoglobin level was lower (P < 0.001) in the HD patients, and echocardiography indicated a larger left atrial diameter (P = 0.004) and lower left ventricular ejection fraction (P = 0.046) in the HD patients than in the non-HD patients. Of the 19 HD patients, 5 developed AF before the introduction of HD, and 14 developed AF 6.9 ± 8.9 years after the introduction of HD. An antithyroid drug was given before ablation to 3 patients in the HD group (16%), including 2 who were given amiodarone.

The ablation procedural characteristics, including procedure-related complications, did not differ between HD patients and non-HD patients (Table 4). The details of the pre-procedural complications are shown in Table 5. A vascular access complication with a hematoma that required a blood transfusion occurred in 1 HD patient. No life-threatening complications were observed in the HD patients, and the incidence of complications did not differ statistically between the HD patients and the non-HD patients. During a mean follow-up of 20 ± 14 months after the initial CA, 12 of the HD patients (63%) and 686 of the non-HD patients (65%) remained free from atrial tachyarrhythmia recurrences (log-rank P = 0.86). The number of patients who underwent the repeated procedure is shown in Figure 1. Eventually, during a mean follow-up period of 17 ± 13 months after the last CA, sinus rhythm was maintained in 15 HD patients (79%) and

### Table 2. Incidence of atrial fibrillation-related symptoms and complications during hemodialysis in patients without atrial fibrillation recurrence after the last catheter ablation (n = 14)

| Symptom/complication | Before ablation | After ablation | P |
|-----------------------|----------------|----------------|---|
| Palpitations          | 9 (64)         | 8 (57)         | 0.699 |
| Vertigo              | 4 (29)         | 2 (14)         | 0.324 |
| Lightheadness         | 6 (43)         | 4 (29)         | 0.430 |
| Chest pain            | 3 (21)         | 2 (14)         | 0.500 |
| Dyspnea              | 6 (43)         | 1 (7)          | 0.038 |
| Interruption of hemodialysis | 3 (21)     | 3 (21)         | 0.676 |

Values are n (%), unless otherwise indicated. Boldface indicates significance.

### Table 3. Comparison of patient characteristics in the hemodialysis (HD) vs non-HD patients

| Variable | HD patients (n = 19) | Non-HD patients (n = 1053) | P |
|----------|----------------------|----------------------------|---|
| Age, y   | 68 ± 8               | 66 ± 11                    | 0.510 |
| Male gender | 14 (74)           | 738 (70)                   | 0.734 |
| Body mass index, kg/m\(^2\) | 23 ± 4               | 25 ± 4                     | 0.048 |
| Paroxysmal AF | 15 (79)         | 608 (58)                   | 0.063 |
| Number of failed AADs | 0.2 ± 0.4          | 0.2 ± 0.4                  | 0.617 |
| AADs before CA | 3 (16)            | 214 (20)                   | 0.443 |
| Class I AADs | 0 (0)                | 70 (7)                     | 0.274 |
| Amiodarone | 2 (11)               | 36 (3)                     | 0.143 |
| Bepridil | 1 (5)                | 102 (10)                   | 0.441 |
| d-Sotalol | 0 (0)                | 7 (1)                      | 0.882 |
| Oral anticoagulants |                       |                            | < 0.001 |
| Warfarin | 19 (100)             | 40 (4)                     | < 0.001 |
| Edoxaban | 0 (0)                | 373 (35)                   | < 0.001 |
| Apixaban | 0 (0)                | 213 (20)                   | 0.014 |
| Dabigatran | 0 (0)              | 299 (28)                   | 0.006 |
| Rivaroxaban | 0 (0)               | 128 (12)                   | 0.087 |
| Congestive heart failure | 5 (26)          | 193 (18)                   | 0.264 |
| Hypertension | 18 (95)             | 590 (56)                   | < 0.001 |
| Diabetes mellitus | 9 (47)              | 159 (15)                   | < 0.001 |
| History of a stroke | 2 (11)              | 112 (11)                   | 0.671 |
| Vascular disease | 6 (32)               | 51 (5)                     | < 0.001 |
| CHADS\(_2\) score | 2.0 ± 1.2          | 1.2 ± 1.1                  | 0.002 |
| CHA\(_2\)DS\(_2\)-VASc score | 3.3 ± 1.5         | 2.1 ± 1.5                  | 0.001 |
| Underlying heart disease |                       |                            |       |
| Valvular | 4 (21)               | 119 (11)                   | 0.165 |
| Ischemic | 4 (21)               | 44 (4)                     | 0.008 |
| Non-ischemic cardiomyopathy | 1 (5)            | 45 (4)                     | 0.569 |
| Smoking: Brinkman index | 480.4 ± 642.9     | 297.5 ± 546.7              | 0.150 |
| Alcohol habit | 9 (47)               | 543 (52)                   | 0.717 |
| Echocardiography |                       |                            |       |
| Left atrial diameter, mm | 44 ± 7            | 39 ± 7                     | 0.004 |
| LV ejection fraction, % | 57 ± 15           | 64 ± 11                    | 0.046 |
| LV end-diastolic diameter, mm | 51 ± 7         | 47 ± 6                     | 0.004 |
| LV end-systolic diameter, mm | 35 ± 9           | 30 ± 7                     | 0.023 |
| TR max PG, mm Hg | 26.6 ± 9.6        | 22.1 ± 5.9                 | 0.053 |
| NT-pro BNP, pg/ml | 14622 ± 1617    | 719 ± 2450                 | 0.001 |
| Hemoglobin, g/dL | 12 ± 1             | 14 ± 2                     | < 0.001 |
| Serum creatinine, mg/dL | 5.9 ± 2.7        | 0.9 ± 0.4                  | < 0.001 |
| eGFR, ml/min per 1.73 m\(^2\) | 11 ± 11          | 63 ± 16                    | < 0.001 |
| Creatinine clearance, ml/min | 14 ± 13         | 77 ± 29                    | < 0.001 |
| Cause of kidney disease |                       |                            |       |
| Diabetic nephropathy | 8 (42)            | —                          |       |
| Nephropenicous | 4 (21)            | —                          |       |
| Chronic glomerulonephritis | 4 (21)          | —                          |       |
| Polycystic kidney disease | 1 (5)            | —                          |       |
| IgA nephropathy | 1 (5)               | —                          |       |
| Crescentic glomerulonephritis | 1 (5)          | —                          |       |
| Duration of HD, y | 6.7 ± 8.4         | —                          |       |
| Free of AADs after the last ablation | 14 (74)       | 826 (78)                   | 0.395 |
| Follow-up period after 1st CA, mo | 28.8 ± 30.2     | 20.3 ± 13.1                | 0.238 |
| Follow-up period after last CA, mo | 24.1 ± 27.7    | 17.0 ± 12.5                | 0.279 |

Values are mean ± standard deviation, or number (%), unless otherwise indicated. Boldface indicates significance.

AAD, antiarrhythmic drug; AF, atrial fibrillation; CA, catheter ablation; CHADS\(_2\) score, Congestive Heart Failure; Hypertension, Age ≥ 75; Diabetes, and Prior Stroke/Transient Ischemic Attack (doubled); CHA\(_2\)DS\(_2\)-VASc score, Congestive Heart Failure, Hypertension, Age (≥ 75 Years) (doubled); Diabetes Mellitus, Stroke (doubled), Vascular Disease, Age (65-74 Years, Sex Category (Female); eGFR, estimated glomerular filtration rate; LV, left ventricular; NT-pro BNP, N-terminal pro brain natriuretic peptide; TR max PG, tricuspid regurgitation maximum pressure gradient.
903 non-HD patients (86%), respectively (log-rank \( P = 0.82; \) Fig. 2). Among the HD patients, 14 (93%) without an arrhythmia recurrence discontinued warfarin therapy, whereas 3 of 4 patients with arrhythmia recurrences continued warfarin therapy due to a previous history of cerebral infarction. During the follow-up period, 1 HD patient (5.3%) and 15 non-HD patients (1.4%) died (Fig. 3). No deaths were associated with the ablation procedure.

### Discussion

The main findings were as follows: (i) the CA of AF significantly improved QoL in the patients undergoing chronic HD therapy; (ii) the CA for AF significantly decreased the incidence of dyspnea during HD in patients without a recurrence of AF; and (iii) the ablation outcome and procedure-related complications in patients undergoing HD therapy were similar to those in non-HD patients.

### Effect of AF ablation on the QoL in HD patients

AF causes impairment of QoL due to the unpredictable onset of palpitations, requirement for medications, and heart failure-associated symptoms. Previous studies have revealed that maintenance of sinus rhythm by CA improves QoL in patients with symptomatic AF.

Although improvement of QoL by CA for AF has been reported, no previous study has evaluated the effect of AF ablation on QoL in AF patients undergoing maintenance HD therapy. The QoL in patients undergoing HD therapy is reported to be worse than that in age-matched subjects from the general population, due to the high burden of comorbidity and complications associated with HD. Seica et al. \(^{21}\) reported that older age, female gender, lower socioeconomic status, and higher educational level were associated with lower QoL scores in patients receiving ongoing HD therapy. Impaired QoL in patients receiving HD therapy is an important issue, as lower QoL is associated with a higher incidence of death and hospitalization. \(^{15}\)

In the present study, QoL significantly improved after CA, as measured by physical functioning, general health perceptions, and symptoms/problems related to kidney disease. QoL has been reported to improve after CA, owing to maintenance of sinus rhythm, reduction of symptoms of AF, or transition to asymptomatic disease states as a result of direct CA effects and improved pharmacologic efficacy. \(^{17-19}\) The improvement in QoL that occurred in the HD patients after CA in the present study might have been achieved by a similar mechanism. Previous studies have reported that adequate medical interventions improve QoL in patients undergoing maintenance HD therapy. Lacson et al. \(^{22}\) reported that achieving an adequate hemoglobin level and albumin level resulted in a significant improvement in the QoL of HD patients. Salhab et al. \(^{23}\) repoted that intradialytic exercise improved QoL in HD patients. AF is one of the most common arrhythmias in patients undergoing HD therapy, \(^{27}\) and AF onset is frequently observed on the day of the HD and specifically during the dialysis procedure itself. \(^{26}\) As most of the antiarrhythmic drugs are difficult to use due to their renal excretion, CA of AF can be an optimal therapeutic option for improving the QoL in patients receiving ongoing HD therapy who are suffering from AF.

### Complications during HD

Although HD technologies have developed in the past few decades, patients who undergo HD still suffer from various intradialytic complications. The most common complications are hypotension and cardiac arrhythmias followed by muscle cramps, dyspnea, palpitation, chest pain, nausea, and vomiting. \(^{25}\) In the present study, the interruption of the HD was mostly due to hypotension, which was still observed even after successful ablation that suppressed AF. The mechanism of hypotension during HD is not fully understood; it is believed to be due to multiple factors, such as rapid fluid removal, cardiovascular system impairment, and failure of compensatory mechanisms for a reduction in venous volume. The present study results indicate that the presence of AF does not always explain the complicated physical response associated with HD in AF patients.
AF-related symptoms in patients undergoing HD therapy

In the present study, dyspnea during HD significantly improved in the patients who did not have AF recurrence, whereas dyspnea did not improve in the patients with AF recurrence after CA. AF causes various symptoms, and AF during HD is the main cause of intradialytic dyspnea, which can be suppressed by successful CA. Palpitation was unchanged before vs after ablation in the present study. Palpitation, one of the main symptoms associated with AF, may be caused by a reactive increase in the heart rate due to fluid removal from the intravascular compartment and other cardiac arrhythmias in patients undergoing HD. Previous studies using Holter monitoring and an implantable cardiac monitor for arrhythmia screening in patients undergoing HD, reported frequent atrial and ventricular premature contractions and nonsustained ventricular tachycardia during HD. Given that palpitations in patients undergoing HD are caused by a variety of factors other than AF, palpitation in the HD patients likely did not improve after CA in the present study.

Four of the 19 HD patients in our study did not have sinus rhythm restoration, even with multiple CA procedures. These patients had a history of long-lasting AF with an extensively enlarged LA, which might limit the efficacy of the CA. Early intervention by CA in HD patients would increase the rate of successful CA leading to an improvement in AF-related symptoms, as recently shown in the general AF population.

Ablation outcomes in patients undergoing HD

Previous studies have evaluated ablation outcomes for AF in patients receiving ongoing HD therapy. These

Figure 1. Flowchart of the ablation outcomes after each procedure in the hemodialysis (HD) and non-HD patients. AF, atrial fibrillation; SR, sinus rhythm.

Figure 2. Kaplan-Meier analysis of the long-term freedom from recurrent atrial fibrillation (AF) after (A) the first catheter ablation (CA) and (B) the last CA in hemodialysis (HD) and non-HD patients.
studies\textsuperscript{11,12} showed that patients on HD therapy had a significantly higher AF recurrence rate than patients not on HD therapy, and HD was associated with AF recurrence. The dilated LA, an excessively activated renin-angiotensin-aldosterone system, and an electrolyte shift after dialysis may cause advanced atrial remodeling, eventually resulting in development of AF.

In the present study, the arrhythmia-free rate after a single ablation and the last CA in the HD patients was similar to that in the non-HD patients, in spite of the fact that the HD patients had a larger LA volume with a lower left ventricular ejection fraction. The discrepancy in results between previous studies and the present study can be explained by the fact that the non-irrigated ablation catheter without contact force sensing was used for CA in previous studies. Since the introduction of the irrigated catheter with contact force-sensing technology, outcomes of AF ablation have dramatically improved,\textsuperscript{28} which might have raised the success rate in HD patients. Supporting this speculation, a recent report evaluating the efficacy of AF ablation in patients receiving ongoing HD therapy. Due to the higher rate of AF recurrence and risk of complication, including bleeding, in HD patients, compared to that of non-HD patients, physicians may have tended to recommend pharmacotherapy rather than CA, resulting in a small sample size. Second, in order to assess the factors associated with QoL that are specific to HD patients, we used the KDQOL-SF 1.3, which was specifically designed to assess QoL in HD patients. Therefore, we did not assess QoL in non-HD patients, and a comparison of the QoL between HD patients and non-HD patients could not be made. Further prospective analyses with a larger population comparing HD patients and non-HD patients are warranted.

Third, most of the patients underwent CA without receiving an antiarrhythmic drug before the ablation, which might have been an unusual practice pattern. Although the current guideline recommends a trial of antiarrhythmic drugs before ablation,\textsuperscript{33} accumulating evidence suggests that a strategy of early rhythm control using CA is associated with better AF-free survival, fewer rehospitalizations, and a decrease in the incidence of progression to persistent AF. In addition, as antiarrhythmic drugs contain a risk of proarrhythmic effect and hemodynamic intolerance when metabolism of the drugs is impaired, CA tended to be chosen as a first-line therapy, especially for HD patients. Finally, not all the patients underwent continuous prolonged electrocardiogram (ECG) recording, such as Holter ECGs, hand-held single-lead ECGs, or implantable loop recorders; therefore, asymptomatic AF recurrence might not have been evaluated adequately.

**Conclusions**

CA for AF significantly improved QoL for HD patients. As the ablation outcome was favorable and was similar to that for non-HD patients, CA of AF is the optimal therapeutic option for improving QoL in patients undergoing HD.

**Acknowledgements**

We thank John Martin for linguistic assistance.

**Funding Sources**

The authors have no funding sources to declare.
Disclosures
The authors have no conflicts of interest to disclose.

References
1. Himmelfarb J, Vanholder R, Mehrrota R, Tonelli M. The current and future landscape of dialysis. Nat Rev Nephrol 2020;16:573-85.
2. Cleary J, Drennan J. Quality of life of patients on haemodialysis for end-stage renal disease. J Adv Nurs 2005;51:577-86.
3. Ortiz A, Covic A, Fliser D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014;383:1831-43.
4. Bakewell AB, Higgins RM, Edmunds ME. Does ethnicity in clinical trials of mortality risk in chronic kidney failure. Lancet 2014;383:1831-43.
5. Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005;46:897-902.
6. Vazquez E, Sanchez-Perales C, Lozano C, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 2003;92:868-71.
7. Genovesi S, Vincenti A, Rossi E, et al. Atrial fibrillation and mortality and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008;51:255-62.
8. Buiten MS, de Bie MK, Rotmans JI, et al. The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart 2014;100:685-90.
9. Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014;311:692-700.
10. Raatikainen MJ, Hakalahi A, Uusimaa P, et al. Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: on-treatment analysis of the randomized controlled MANTRA-PAF trial. Int J Cardiol 2015;198:108-14.
11. Takigawa M, Kuwashara T, Takahashi A, et al. The impact of haemodialysis on the outcomes of catheter ablation in patients with paroxysmal atrial fibrillation. European 2014;16:327-34.
12. Sairaku A, Yoshida Y, Kamiya H, et al. Outcomes of ablation of paroxysmal atrial fibrillation in patients on chronic hemodialysis. J Cardiovasc Electrophysiol 2012;23:1289-94.
13. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017;14:e275-444.
14. Green J, Fukuhara S, Shinzato T, et al. Translation, cultural adaptation, and initial reliability and multirait testing of the Kidney Disease Quality of Life instrument for use in Japan. Qual Life Res 2001;10:93-100.
15. Mapes DL, Lopes AA, Satayatham S, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2003;64:339-49.
16. Miura YGJ, Fukuhara S. Manual of the Kidney Disease Quality of Life (KDQOL) instrument. Japanese version 1.3. Kyoto, Japan: Qualitest, 2020.
17. Wokhuu A, Monahan KH, Hodge DO, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol 2010;55:2308-16.
18. Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1275-85.
19. Blomstrom-Lundqvist C, Gigueraison S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA 2019;321:1059-68.
20. DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 1997;30:204-12.
21. Seica A, Segall L, Verzan C, et al. Factors affecting the quality of life of hemodialysis patients from Romania: a multicentric study. Nephrol Dial Transplant 2009;24:626-9.
22. Lacson E Jr, Xie J, Lin SF, et al. Association between achievement of hemodialysis quality-of-care indicators and quality-of-life scores. Am J Kidney Dis 2009;54:1098-107.
23. Saliba N, Karavelian, Kooman J, Fiacchadori E, El Khoury CF. Effects of intradialytic aerobic exercise on hemodialysis patients: a systematic review and meta-analysis. J Nephrol 2019;32:549-66.
24. Davenport A. Intradialytic complications during hemodialysis. Hemodial Int 2006;10:162-7.
25. Kimura K, Tabei K, Asano Y, Hosoda S. Cardiac arrhythmias in hemodialysis patients. A study of incidence and contributory factors. Nephron 1989;53:201-7.
26. Wong MC, Kalman JM, Pedagogos E, et al. Temporal distribution of arrhythmic events in chronic kidney disease: highest incidence in the long interdialytic period. Heart Rhythm 2015;12:2047-55.
27. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305-16.
28. Thomas SP, Aggarwal G, Boyd AC, Jin Y, Ross DL. A comparison of open irrigated and non-irrigated tip catheter ablation for pulmonary vein isolation. Europace 2004;6:330-5.
29. Hayashi M, Kaneko S, Shimano M, et al. Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients. Nephrol Dial Transplant 2014;29:160-7.
30. Salih M, Darrat Y, Ibrahim AM, et al. Clinical outcomes of adjunctive posterior wall isolation in persistent atrial fibrillation: a meta-analysis. J Cardiovasc Electrophysiol 2020;31:1394-402.
31. Takahashi Y, Yamaguchi T, Fukui A, et al. Impact of renal dysfunction on left atrial structural remodeling and recurrence after catheter ablation for atrial fibrillation- a propensity score matching analysis. Circ J 2020;84:1254-60.
32. Takamiya T, Nitta J, Ibara O, et al. Cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation in hemodialysis patients. Heart Vessels 2020;35:1709-16.
33. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 2019;140:e125-51.

Supplementary Material
To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca/ and at https://doi.org/10.1016/j.cjco.2022.05.009.